Comparison Chart BioLineRx Ltd.

Equities

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 04:56:35 2024-06-13 EDT			5-day change	1st Jan Change
17.4 ^ILa	+1.16%		-1.69%	-54.45%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

		Sector	Change	5d. change	1st Jan change	1-year change	5-years change	Capi.	ST	MT	LT
	BIOLINERX LTD.	Bio Therapeutic Drugs	+1.16%	-1.69%	-54.45%	-56.50%	-86.28%	55.96M